Tarsus Pharmaceuticals, Inc. (TARS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 102,660 | 78,335 | 48,118 | 40,813 |
| Total operating expenses | 124,844 | 104,615 | 73,280 | 74,115 |
| Loss from operations before other income (expense) | -22,184 | -26,280 | -25,162 | -33,302 |
| Realized/unrealized (loss) gain on equity investments | - | - | - | -6 |
| Other income (expense), net | -145 | -81 | 67 | -59 |
| Interest income | 4,229 | 3,454 | 4,120 | 4,130 |
| Interest expense | 2,240 | 2,213 | 2,445 | 2,109 |
| Loss on debt extinguishment | - | - | - | -1,944 |
| Total other income (expense), net | 1,844 | 1,160 | 1,742 | 12 |
| Net loss | -20,340 | -25,120 | -23,420 | -33,290 |
| Unrealized gain (loss) on marketable securities and cash equivalents | -46 | -94 | 522 | -113 |
| Comprehensive loss | -20,386 | -25,214 | -22,898 | -33,403 |
| Net loss per share - basic (usd per share) | -0.48 | -0.64 | -0.61 | -0.88 |
| Net loss per share - diluted (usd per share) | -0.48 | -0.64 | -0.61 | -0.88 |
| Weighted-average shares outstanding - diluted (in shares) | 42,360,452 | 39,345,359 | 38,381,968 | 37,823,233 |
| Weighted-average shares outstanding, basic (in shares) | 42,360,452 | 39,345,359 | 38,381,968 | 37,823,233 |